Citations

Clear

1792 citation(s) found for "Stephanie".

SUN-198 Vaginal Microbial Diversity Changes across the Menstrual Cycle in Healthy Young Women
Song, Stephanie , Zhu, Jade E., Acharya, Kalpana D. , Walther-António, Marina , Tetel, Marc J. , Chia, Nicholas

Mayo Clinic

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-sun-198 Get It

Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
Gangat, Naseema , Marinaccio, Christian , Swords, Ronan , Watts, Justin M. , Rademaker, Alfred , Fought, Angela J. , Frankfurt, Olga, Altman, Jessica K. , Wen, Qiang , Farnoud, Noushin , Famulare, Christopher , Patel, Akshar, Vallapureddy, Rangit, Barath, Stephanie, Graf, Amy, Handlogten, Amy, Zblewski, Darci, Patnaik, Mrinal M. , Al‐Kali, Aref , Dinh, Yvonne, Prahl, Kristen Englund, Patel, Shradha, Nobrega, Juan Carlos , Tejera, Dalissa, Thomassen, Amber , Gao, Juehua , Rampal, Raajit K. , Tefferi, Ayalew , Stein, Brady L. , Crispino, John D. , Vallapureddy, Rangit R, Rampal, Raajit K , Giles, Francis Joseph , Crispino, John D , Gurbuxani, Sandeep K. , Wen, Qiang Jeremy, TAPIA-CONYER, ROBERTO C. , Ji, Peng Cheng

Mayo Clinic

Clinical Cancer Research | May 7, 2019 | Volume: 25 | Issue: 16 | Pages: 4898-4906

10.1158/1078-0432.ccr-19-1005 | PMID 31061068 Get It

Abstract Purpose: Myelofibrosis is characterized by bone marrow fibrosis, atypical megakaryocytes, splenomegaly, constitutional symptoms, thrombotic and hemorrhagic complications, and a risk of evolution to acute leukemia. The JAK kinase inhibitor ruxolitinib provides therapeutic benefit, but the effects are limited. The purpose of this study was to determine whether targeting AURKA, which has been shown to increase maturation of atypical megakaryocytes, has potential benefit for patients with myelofibrosis. Patients and Methods: Twenty-four patients with myelofibrosis were enrolled in a phase I study at three centers. The objective of the study was to evaluate the safety and preliminary efficacy of alisertib. Correlative studies involved assessment of the effect of alisertib on the megakaryocyte lineage, allele burden, and fibrosis. Results: In addition to being well tolerated, alisertib reduced splenomegaly and symptom burden in 29% and 32% of patients, respectively, despite not consistently reducing the degree of inflammatory cytokines. Moreover, alisertib normalized megakaryocytes and reduced fibrosis in 5 of 7 patients for whom sequential marrows were available. Alisertib also decreased the mutant allele burden in a subset of patients. Conclusions: Given the limitations of ruxolitinib, novel therapies are needed for myelofibrosis. In this study, alisertib provided clinical benefit and exhibited the expected on-target effect on the megakaryocyte lineage, resulting in normalization of these cells and reduced fibrosis in the majority of patients for which sequential marrows were available. Thus, AURKA inhibition should be further developed as a therapeutic option in myelofibrosis. See related commentary by Piszczatowski and Steidl, p. 4868
Case 3: Bradycardia in a Vigorous Newborn
Timothy, Leander D. , Stetson, Raymond C. , Qureshi, M. Yasir , Wilkins, Stephanie N., Asay, Garth F., Qureshi, Muhammad Yasir, Qureshi, Muhammad Y

Mayo Clinic

NeoReviews | May 1, 2019 | Volume: 20 | Issue: 5 | Pages: e298-e301

10.1542/neo.20-5-e298 | PMID 31261083 Get It

Utilization of Overnight Pulse Oximetry in Fibromyalgia Patients
Clark, Stephanie , Salonen, Bradley R. , BS, Neha V Reddy, Mohabbat, Arya B. , Reddy, Neha V , Clark, Stephanie D, Reddy Bs, Neha V

Mayo Clinic

Global Advances in Health and Medicine | May 1, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2164956119847125 | PMID 31069165 Get It

Objective To assess whether the Berlin Sleep Questionnaire and the Snoring, Tired, Observed, Pressure, Body mass, Age, Neck, and Gender questionnaire (STOP-BANG) might be suitable replacements for an overnight sleep pulse oximetry as screening tools for sleep disordered breathing in patients with fibromyalgia. Participants: From June 8, 2018 through July 25, 2018, adult patients with a confirmed diagnosis of fibromyalgia (via the 1990 and/or 2010 American College of Rheumatology Fibromyalgia Classification Criteria) who attended Mayo Clinic’s Fibromyalgia Treatment Program were invited to participate in the study. Methods: The design was a prospective comparative study with a retrospective chart review component. Participants completed 2 validated surveys: the Berlin Sleep Questionnaire and the STOP-BANG. Medical records were reviewed for demographic information and overnight pulse oximetry test results. Results: Results from both questionnaires indicate that there is an association between sleep apnea risk category (defined by questionnaire) and oximetry results. Fisher’s exact test for STOP-BANG and Berlin Sleep Questionnaire are statistically significant ( P < .001), indicating that participants at high risk for sleep apnea (based on the questionnaires) had a greater prevalence of abnormal oximetry results than those at low risk for sleep apnea. Participants who were classified as high risk (85.7%) or intermediate risk (61.5%) on the STOP-BANG questionnaire for sleep apnea had abnormal oximetry results. Participants who scored as high risk (85.7%) for sleep apnea on the Berlin Sleep Questionnaire had abnormal oximetry results. Conclusions: In patients with fibromyalgia, the Berlin Sleep Questionnaire and the STOP-BANG questionnaires could be beneficial in determining the probability of obstructive sleep apnea and the subsequent need for pulse oximetry testing, in higher risk patients.
Patient-oriented education and visual-aid intervention are inadequate to identify patients with potential capsule retention: a prospective randomized study
Al‐Bawardy, Badr , Kamboj, Amrit K. , Desai, Shiv, Gorospe, Emmanuel C., Bruining, David H. , Gostout, Christopher J., Larson, Mark V., Nehra, Vandana, Leggett, Cadman L. , Szarka, Lawrence A., Watson, Robert E. , Rajan, Elizabeth , Gorospe, Emmanuel, Hansel, Stephanie L. , Leggett, Cadman L , Murray, Joseph A.

Mayo Clinic

Scandinavian Journal of Gastroenterology | April 30, 2019 | Volume: 54 | Issue: 5 | Pages: 662-665

10.1080/00365521.2019.1608465 | PMID 31034255 Get It

Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies
Peterson, Jess F. , Pitel, Beth A. , Smoley, Stephanie A., Vasmatzis, George , Smadbeck, James B. , Greipp, Patricia T. , Mangaonkar, Abhishek A. , Thompson, Carrie A. , Chen, Dong , Viswanatha, David S., Parikh, Sameer A , Chen, Dong , Peterson, Jess F , Pitel, Beth A , Greipp, Patricia T , Baughn, Linda B. , Ketterling, Rhett P. , Parikh, Sameer A.

Mayo Clinic

Blood Advances | April 23, 2019 | Volume: 3 | Issue: 8 | Pages: 1298-1302

10.1182/bloodadvances.2019031450 | PMID 31015206 Get It

Key Points This article characterizes a cryptic IGH/CCND1 rearrangement in MCL by NGS. Mate-pair sequencing can help in accurately diagnosing MCL in cases of cyclin-D1–positive B-cell lymphoma with negative CCND1 FISH studies.
Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile
Larish, Alyssa M., Dickson, Rozalin R. , Kudgus, Rachel A. , McGovern, Renee M., Hooten, W. Michael , Nicholson, Wayne T. , Vaughan, Lisa E. , Burnett, Tatnai L. , Laughlin-Tommaso, Shannon K., Green, Isabel C. , Reid, Joel M. , Faubion, Stephanie S.

Mayo Clinic

The Journal of Sexual Medicine | April 19, 2019 | Volume: 16 | Issue: 6 | Pages: 763-766

10.1016/j.jsxm.2019.03.003 | PMID 31010782 Get It

ABSTRACT Background Vaginal diazepam is frequently used to treat pelvic floor tension myalgia and pelvic pain despite limited knowledge of systemic absorption. Aim To determine the pharmacokinetic and adverse event profile of diazepam vaginal suppositories. Methods We used a prospective pharmacokinetic design with repeated assessments of diazepam levels. Eight healthy volunteers were administered a 10-mg compounded vaginal diazepam suppository in the outpatient gynecologic clinic. Serum samples were collected at 0, 45, 90, 120, and 180 minutes; 8, 24, and 72 hours; and 1 week following administration of a 10-mg vaginal suppository. The occurrence of adverse events was assessed using the alternate step and tandem walk tests, the Brief Confusion Assessment Method, and numerical ratings. Plasma concentrations of diazepam and active long-acting metabolites were measured. Pharmacokinetic parameters were calculated by standard noncompartmental methods. Results The mean peak diazepam concentration (Cmax) of 31.0 ng/mL was detected at a mean time (Tmax) of 3.1 hours after suppository placement. The bioavailability was found to be 70.5%, and the mean terminal elimination half-life was 82 hours. The plasma levels of temazepam and nordiazepam peaked at 0.8 ng/mL at 29 hours and 6.4 ng/mL at 132 hours, respectively. Fatigue was reported by 3 of 8 participants. Clinical Implications Serum plasma concentrations of vaginally administered diazepam are low; however the half-life is prolonged. Strengths & Limitations Strengths include use of inclusion and exclusion criteria aimed at mitigating clinical factors that could adversely impact diazepam absorption and metabolism, and the use of an ultrasensitive LC-MS/MS assay. Limitations included the lack of addressing the efficacy of vaginal diazepam in lieu of performing a pure pharmacokinetic study with healthy participants. Conclusion Vaginal administration of diazepam results in lower peak serum plasma concentration, longer time to peak concentration, and lower bioavailability than standard oral use. Providers should be aware that with diazepam’s long half-life, accumulating levels would occur with chronic daily doses, and steady-state levels would not be reached for up to 1 week. This profile would favor intermittent use to allow participation in physical therapy and intimacy.
Ectopic Ocular Surface Calcification in Patients With Hypophosphatasia Treated With Asfotase Alfa
Gospe, Sidney M. , Santiago-Turla, Cecilia, DeArmey, Stephanie, Cummings, Thomas J. , Bhatti, M. Tariq , Kishnani, Priya Sunil

Mayo Clinic

Cornea | April 9, 2019 | Volume: 38 | Issue: 7 | Pages: 896-900

10.1097/ico.0000000000001947 | PMID 30969260 Get It

Purpose: To assess for ectopic ocular calcification in a series of patients with hypophosphatasia (HPP) treated with asfotase alfa, a recombinant tissue-nonspecific alkaline phosphatase. Methods: This is a retrospective analysis of subjects enrolled at Duke University Medical Center in ENB-009-10 (ClinicalTrials.gov: NCT01163149), a randomized controlled trial of asfotase alfa in adolescents and adults with HPP. Seven patients between the ages of 45 and 66 years diagnosed with HPP based on clinical features and low serum alkaline phosphatase levels were enrolled at our site. Subjects were randomized to receive either daily subcutaneous injections of asfotase alfa or no treatment. After 24 weeks, during the open-label extension phase, all subjects received treatment for at least 4 years. All subjects underwent comprehensive eye examinations at baseline and at 24-week intervals throughout the study to assess for development of ocular calcifications. Results: By week 120, all 7 subjects developed asymptomatic white refractile deposits in the interpalpebral perilimbal conjunctiva. Biopsy of the conjunctival lesions in 2 subjects revealed elastosis with subepithelial calcification. The lesions were nonprogressive and in 5 subjects exhibited some degree of regression. Conclusions: Asfotase alfa was invariably associated with development of mild focal conjunctival calcification, likely through disinhibition of hydroxyapatite crystal propagation. The calcifications were not symptomatic or vision-threatening and should not preclude enzyme replacement therapy for patients with this rare and often debilitating disease.
Curricular Development and Implementation of a Longitudinal Integrative Medicine Education Experience for Trainees and Health-Care Professionals at an Academic Medical Center
Cutshall, Susanne M. , Khalsa, Tejinder, Chon, Tony Y. , Vitek, Sairey M. , Clark, Stephanie , Blomberg, Debra , Bhagra, Anjali , Khalsa, Tejinder K, Clark, Stephanie D, Blomberg, Debra L, Mustafa, Rafid

Mayo Clinic

Global Advances in Health and Medicine | April 1, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2164956119837489 | PMID 30967973 Get It

A growing number of patients and consumers are seeking integrative medicine (IM) approaches as a result of increasing complex medical needs and a greater emphasis on prevention and health promotion. Health-care professionals need to have knowledge of the evidence-based IM resources that are safe and available to patients. Medical institutions have acknowledged the need for education and training in various IM modalities and whole-health approaches in medical curricula. There is a strong need to develop and incorporate well-structured IM curricula across all levels of learning and practice within medicine. This article provides an example of the development, implementation, impact, and assessment of IM education curricula across all learner levels at a large academic medical center.